• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Emergency

Sublingual dexmedetomidine reduces agitation in patients with acute agitation associated with bipolar disorder

byYuchen DaiandMichael Pratte
February 25, 2022
in Emergency, Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Among patients with mild to moderate agitation associated with bipolar disorder, treatment with sublingual dexmedetomidine resulted in significantly greater reduction in the agitation score compared to placebo.

2. Further research is required to understand the spectrum of patients with bipolar disorder and agitation for whom this investigational treatment would be effective and feasible.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The management of acute agitation in patients with bipolar disorder requires a patient-centred approach where the goal pharmacological treatment should be to induce calm without oversedation. Dexmedetomidine is an α2-adrenergic receptor agonist approved for procedural sedation and anesthesia. This study assessed the efficacy of a single dose of sublingual dexmedetomidine in reducing symptoms of acute agitation associated with bipolar disorder. The main endpoint was the mean change from baseline at 2 hours for the Positive and Negative Syndrome Scale-Excited Component (PEC) total score (5 – absence of agitation to 35 – extremely severe). The secondary endpoint was the earliest time to a statistically significant delta in PEC score from baseline for the intervention groups vs placebo. Among 380 patients with mild to moderate agitation associated with bipolar disorder, treatment with sublingual dexmedetomidine 180 μg or 120 μg resulted in a statistically significant greater reduction in the agitation score at 2 hours compared to placebo. Further research is required to understand the spectrum of patients with bipolar disorder and agitation for whom this investigational treatment would be effective and feasible. A limitation of this study was that it only evaluated efficacy and adverse effects of sublingual dexmedetomidine following a single episode of mild to moderate agitation, reducing the generalizability of the study’s findings in clinical context.

Click to read the study in JAMA

Click to read an accompanying editorial in JAMA

Relevant Reading: Safety and efficacy of dexmedetomidine as a sedative agent for performing awake intubation: a meta-analysis

RELATED REPORTS

Religion and spirituality dimensions may be beneficial in bipolar disorder symptoms

Wellness Check: Spirituality

The 2 Minute Medicine Podcast Episode 2

In-Depth [randomized clinical trial]: This randomized, double-blind, placebo-controlled trial enrolled 380 patients (mean age, 45.6 years; 54.8% women; 56.1% Black individuals) across 15 US centers between February and April 2020. Participants were randomized to sublingual dexmedetomidine 180 μg (n = 127), sublingual dexmedetomidine 120 μg (n = 127), or placebo (n = 126). The mean PEC total score at baseline was 18.0. At 2 hours after taking the medication, the mean change from baseline in PEC total score were −10.4 for sublingual dexmedetomidine 180 μg, −9.0 for sublingual dexmedetomidine 120 μg, and −4.9 for placebo. Treatment effects were observed 20 minutes after oral administration of sublingual dexmedetomidine (least-square mean difference for 180 μg, −1.1 [97.5%CI, −2.0 to −0.2]; P = .007; for 120 μg, −1.0 [97.5%CI, −1.9 to −0.1]; P = .009). Adverse events were observed in 35.7% of patients taking 180 μg of dexmedetomidine, 34.9% taking 120 μg, and 17.5% taking placebo, where the most common adverse effect was somnolence (21.4% vs 20.6% vs 4.8%).

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: agitationBipolar Disorderdexmedetomidine
Previous Post

Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer

Next Post

2 Minute Medicine Rewind February 28, 2022

RelatedReports

Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse
Chronic Disease

Religion and spirituality dimensions may be beneficial in bipolar disorder symptoms

December 2, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Wellness

Wellness Check: Spirituality

December 1, 2022
2MM Podcast

The 2 Minute Medicine Podcast Episode 2

November 22, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: An Organ Donor Crisis, A Closer Look at Bipolar Disorder, What to know about Processed Foods, and Key Issues in Men’s Health

November 15, 2022
Next Post
Ticagrelor reversal agent provides immediate and sustained effect

2 Minute Medicine Rewind February 28, 2022

Quick Take: Efficacy of short-term treatment of internet and computer game addiction

Video game interventions may improve depressive symptoms in adolescents and young adults

Patient Basics: Nosebleed (Epistaxis)

Capecitabine maintenance therapy for metastatic nasopharyngeal carcinoma improves progression-free survival

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Momelotinib reduces symptom burden compared to danazol in patients with myelofibrosis
  • Machine renal perfusion reduces delayed graft function after transplantation
  • COVID-19 mRNA vaccines are safe and effective in children aged 5 to 11 years
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options